COMPANY RESEARCHAPAC-origin international CRO with disclosed China teams, offices and site partnerships. Relevant to biotech China delivery comparisons; IIT support requires project-level confirmation.
Profile review: 2026-11-06 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Large-molecule PK, ADA, neutralizing antibodies and clinical laboratory testing
Specialist contract research/testing services
APAC-origin international CRO with disclosed China teams, offices and site partnerships. Relevant to biotech China delivery comparisons; IIT support requires project-level confirmation.
International delivery scope: International CRO with China operations
IIT evidence: IIT capability not established by reviewed sources
Individual program detail is not recorded. Consult the original sources below.
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
CSPC announced initiation of the first Chinese center for SYS6055-003, a Phase 1/2 trial in relapsed or refractory B-cell non-Hodgkin lymphoma. SYS6055 uses lentiviral vectors to generate CD19-targeting CAR-T cells in vivo. The company said recruitment and screening are underway following October clinical-trial authorization. Center initiation does not establish patient dosing, efficacy, or marketing approval.
The China National Center for Biotechnology Development published its fifteenth batch of biomedical clinical research filings on November 4. Seven projects completed filing between October 27 and November 4. The notice emphasizes institutional responsibility, internal quality management, training, data traceability, and participant protection. Filing concerns the research pathway; it is not evidence of therapeutic efficacy or product marketing authorization.
A Bioanalysis paper describes development and prevalidation of a Luminex xMAP assay for simultaneous domain-specific anti-drug antibody detection. Using PEGylated Cas9 as a model, the authors report adjustable bead ratios and on-demand coupling to accommodate different minimum required dilutions. The original abstract supports assay feasibility, rather than universal validation across multidomain therapeutics or demonstrated clinical benefit.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.